Navigation Links
Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models

ressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, risks that favorable efficacy and safety results in animal models will not be replicated in humans, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


     Laura S. Choi                   Jean Mantuano

     Investor Relations              Corporate Communications (media)

Phone: 609-430-2880, x2216, Phone: 609-430-2880, x2221

CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, ext. 2216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, ext.2221, both of Medarex, Inc.

Web site: http://www.medarex.com/

Company News On-Call: http://www.prnewswire.com/comp/108265.html/

T
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/19/2014)... PHILADELPHIA , Sept. 19, 2014  PCI ... Services International (Biotec).  Biotec is a leading provider ... Services headquartered in Bridgend, Wales ... .  The addition significantly expands PCI,s presence in ... medicinal products by adding packaging, storage and distribution ...
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... U.S. Food and Drug Administration (FDA) approved ... of INTELENCE ® (etravirine), a non-nucleoside reverse transcriptase ... virus (HIV-1) in treatment-experienced adults with resistance to an ... The recommended oral dose of INTELENCE tablets is 200 ...
... KONG, Jan. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech ... with its subsidiary collectively as the "Group" - 801.HK), ... announce that the Company has obtained the approvals from ... Futures Bureau for its proposed offering and listing of ...
Cached Medicine Technology:FDA Approves New Dosage Strength for INTELENCE® 2FDA Approves New Dosage Strength for INTELENCE® 3FDA Approves New Dosage Strength for INTELENCE® 4FDA Approves New Dosage Strength for INTELENCE® 5Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering 2
(Date:9/19/2014)... 19, 2014) Shahram Majidi, M.D., a second-year ... George Washington University School of Medicine and Health ... Heart Association to study the presence of diffuse ... hemorrhage (ICH). , "According to epidemiological studies, intracerebral ... all strokes, but is the least treatable form ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... 19, 2014 BCC Research reveals in ... GLOBAL MARKETS , the global market for human antifungal ... by 2018, with a five-year compound annual growth rate ... growing at a steady 3.8% CAGR. , Given the ... sales, coupled with the incidence of increasing mortality and ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Capital ... Reed Ference, is excited to announce the latest ... periodontal disease, gingivitis and those needing dental implants. ... LANAP® laser treatment removes the fear factor normally ... stitches, less discomfort and bleeding make, this procedure ...
(Date:9/19/2014)... Singulair, developed by Merck, is a CysLT1 ... (LTD4). LTD4 belongs to the family of Cys-LTs, which ... mast cells and eosinophils, and which bind to the ... there are higher concentrations of Cys-LTs in the airways ... production of CysLTs is increased in asthmatics, particularly during ...
Breaking Medicine News(10 mins):Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4
... disease (COPD) are more likely to suffer worse consequences ... due to be presented at the American Thoracic Society ... play a role in the increased death rate seen ... M.D., Assistant Professor of Medicine at the University of ...
... as many patients in the chronic disease management programs ... Boon Wan who was addressing he third National Disease ... of death and human suffering remains a fact as ... could be an effective tool in such circumstances. To ...
... socioeconomic status have a higher level of stress hormones in ... the newest issue of Psycosomatic Medicine, this increased level is ... study does not have to do with poverty, per se,’ ... Carnegie Mellon University. He said the purpose of the study ...
... the popular belief that the effect of war and ... soldier’s partner and children//. It highlights that war trauma ... ,Psychiatrist Arend Veeninga, in the Dutch monthly ... to the theory that ‘war trauma is infectious’. ...
... Researchers at Baylor University Medical Center at Dallas and ... to introduce insulin genes into the pancreas//. , ... (blood sugar) to enter the cells of the body ... ultrasound-targeted micro bubble destruction (UTMD), delivers these insulin genes ...
... the Internet, cancer patients find it hard to locate ... new study has found. Surprisingly, most cancer patients seek ... cancer information on their own, reveals the study conducted ... ,Despite the ease and availability of Internet ...
Cached Medicine News:Health News:Lung Disease More Severe In Women Than Men 2Health News:Lung Disease More Severe In Women Than Men 3Health News:Hormone Levels Increase Due To Socioeconomic Stress 2Health News:Bubble Technique on the cards For Treatment of Type I diabetes 2Health News:Internet Searches Fail To Give Useful Information To Cancer Patients 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: